



## **ROVI completes the manufacture of the first batches of Moderna vaccine for EU**

**Madrid – 13 January 2021** – Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the research, development and marketing of biological specialties and a manufacturer with a high degree of technological differentiation, confirms that it has completed the manufacturing of the first batches of the COVID-19 Vaccine Moderna for European Union at its Madrid facilities.

After obtaining the conditional marketing authorisation (CMA) from the European Commission on 6 January, Moderna and ROVI have collaborated to maximise efficiency to make the COVID-19 Vaccine Moderna available to citizens in record time.

ROVI completed the installation of a new production line with equipment for formulation, aseptic filling, automatic visual inspection and labelling, in order to support the production of millions of doses of Moderna's vaccine to supply markets outside the U.S.A. Furthermore, it has recruited additional personnel for the manufacturing and analysis operations.

Coinciding with the arrival of the first batches in European countries, including Spain, ROVI's management highlights the work of its team over recent months, which has made the increase in the manufacturing capacity possible, as well as the production of the first vials that are now reaching the European markets in record time and will help to immunise the population. *"We are very satisfied with ROVI's contribution, which will make it part of the solution, in record time, to this pandemic that is affecting all of us, and we will continue to support Moderna in the continued supply of its vaccine",* they explain.

The European Commission granted a conditional marketing authorisation (CMA) for the COVID-19 Vaccine Moderna on 6 January 2021, based on the recommendation of the European Medicines Agency (EMA) for its use for active immunisation to prevent COVID-19 caused by the SARS-CoV-2 virus in persons aged 18 or over. To date, the distribution of the COVID-19 Vaccine Moderna has likewise been authorised in the United States, Canada, Israel and the United Kingdom. Iceland, Norway and Switzerland have also granted marketing authorisations.

## **About ROVI**

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy France and Poland, and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is already marketed in 56 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its in-house developed enoxaparin biosimilar in Europe. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit [www.rovi.es](http://www.rovi.es).

## **ROVI's contacts**

### **Media**

#### **ATREVIA**

Patricia Cobo | [pcobo@atrevia.com](mailto:pcobo@atrevia.com) | 659 736 124

Carlos C. Ungría | [cungria@atrevia.com](mailto:cungria@atrevia.com) | 672 447 065